文献速递造血干细胞移植与细胞治疗

那他珠单抗联合标准糖皮质激素治疗高危急性移植物抗宿主病的2期研究

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心2期研究纳入75例新发AA2/3评分高危急性GVHD患者,在糖皮质激素基础上加用那他珠单抗,81%在开始激素后2天内用药,耐受良好。与MAGIC数据库中150例匹配的单纯激素对照相比,总缓解率、完全缓解率、12个月非复发死亡率和总生存均无显著差异。

要点

  • 那他珠单抗联合糖皮质激素耐受良好,未出现发生率>10%的治疗期不良事件。
  • 联合组与单纯激素组总缓解率60% vs 58%(P=.67),完全缓解率48% vs 48%(P=1.0),均无显著差异。
  • 12个月非复发死亡率38% vs 39%(P=.80),总生存46% vs 54%(P=.48),均无显著差异。

核心结论

  • 在这项基于生物标志物的多中心2期研究中,那他珠单抗联合糖皮质激素未能改善新诊断高危GVHD患者的结局。

研究设计与样本

  • 多中心2期研究,纳入75例可评估的新发AA2/3评分高危急性GVHD患者,接受那他珠单抗联合糖皮质激素作为一线治疗。
  • 81%的患者在开始糖皮质激素后2天内接受那他珠单抗。
  • 与MAGIC数据库中150例匹配良好、以单纯糖皮质激素为一线治疗的对照进行比较。
  • 试验注册号NCT02133924。

主要发现

  • 治疗耐受良好,未出现发生率>10%的治疗期不良事件。
  • 联合组与单纯激素组总缓解率60% vs 58%(P=.67),完全缓解率48% vs 48%(P=1.0),包括相关亚组均无显著差异。
  • 12个月非复发死亡率联合组38% vs 对照组39%(P=.80),总生存联合组46% vs 对照组54%(P=.48),均无显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) of the gastrointestinal (GI) tract is the main cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Ann Arbor (AA) scores derived from serum biomarkers at onset of GVHD quantify GI crypt damage; AA2/3 scores correlate with resistance to treatment and higher NRM. We conducted a multicenter, phase 2 study using natalizumab, a humanized monoclonal antibody that blocks T-cell trafficking to the GI tract through the α4 subunit of α4β7 integrin, combined with corticosteroids as primary treatment for patients with new onset AA2/3 GVHD. Seventy-five patients who were evaluable were enrolled and treated; 81% received natalizumab within 2 days of starting corticosteroids. Therapy was well tolerated with no treatment emergent adverse events in >10% of patients. Outcomes for patients treated with natalizumab plus corticosteroids were compared with 150 well-matched controls from the MAGIC database whose primary treatment was corticosteroids alone. There were no significant differences in overall or complete response between patients treated with natalizumab plus corticosteroids and those treated with corticosteroids alone (60% vs 58%; P = .67% and 48% vs 48%; P = 1.0, respectively) including relevant subgroups. There were also no significant differences in NRM or overall survival at 12 months in patients treated with natalizumab plus corticosteroids compared with controls treated with corticosteroids alone (38% vs 39%; P = .80% and 46% vs 54%; P = .48, respectively). In this multicenter biomarker-based phase 2 study, natalizumab combined with corticosteroids failed to improve outcome of patients with newly diagnosed high-risk GVHD. This trial was registered at www.clinicaltrials.gov as # NCT02133924.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Al Malki MM, London K, Baez J, et al. Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease. Blood Adv. 2023. PMID: 37235690. doi:10.1182/bloodadvances.2023009853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。